Ingredient
2-Methylresorcinol
2-Methylresorcinol is flagged for pregnancy, trying to conceive, breastfeeding, postpartum, PCOS and general use. The concern behind the strongest flag is endocrine disruptor and absorbed into the body.
- 2-Methyl-1,3-Benzenediol
- Orcinol
- 5-Methylresorcinol
Verdict by profile
Truva checks every ingredient against six profiles. Jump to any of them for the full assessment.
- Strongest verdict
- Not Recommended
- Its verdict for pregnancy, the profile this one is worst in
- Profiles flagged
- 6 of 6
- Counting avoid, high risk and medium risk
- Irritancy
- 2 of 5
- Higher means more likely to sting or redden
2-Methylresorcinol and pregnancy
Not Recommended
- Endocrine disruptor
- Absorbed into the body
2-Methylresorcinol is a phenolic compound structurally related to resorcinol, which is used in hair dyes and some skin treatments. Resorcinol and its derivatives can be absorbed through the skin and have shown endocrine-disrupting potential in laboratory studies. According to the SCCS, resorcinol derivatives raise concerns due to limited safety data and potential for systemic absorption. While specific human studies on 2-methylresorcinol during pregnancy are lacking, the mechanism of action and structural similarity to compounds with known endocrine effects warrant caution. The FDA has not specifically evaluated this ingredient for pregnancy safety. Most dermatologists and obstetricians recommend avoiding phenolic compounds with potential endocrine-disrupting properties during pregnancy due to theoretical risks to fetal development. Given the data gaps and the availability of safer alternatives for hair coloring and skincare, avoiding 2-methylresorcinol during pregnancy is the conservative approach.
2-Methylresorcinol and breastfeeding
Caution Advised
- Absorbed into the body
- Infant exposure
2-Methylresorcinol can be absorbed systemically through the skin, particularly when used in hair dye formulations or leave-on products. Data on its excretion into breast milk is not available, but structurally similar phenolic compounds can potentially transfer to milk. Given the limited safety data and potential endocrine-disrupting properties of resorcinol derivatives, caution is advised during breastfeeding. While the risk is lower than during pregnancy (as it doesn't directly affect a developing fetus), exposure to the breastfed infant through breast milk remains a theoretical concern. Many dermatologists suggest postponing use of ingredients with uncertain safety profiles until after weaning, especially when safer alternatives exist. If using products containing 2-methylresorcinol, avoid application to areas that come in contact with the infant.
2-Methylresorcinol and postpartum
Caution Advised
- Irritant
- Common allergen
For women who are not breastfeeding, 2-methylresorcinol carries lower reproductive risks, though the ingredient still has potential for skin irritation and allergic reactions. The limited safety data remains a concern regardless of reproductive status. Postpartum skin can be more sensitive due to hormonal fluctuations, making irritation from phenolic compounds more likely. If considering products with this ingredient, patch testing is recommended, and safer brightening alternatives are widely available.
2-Methylresorcinol and trying to conceive
Not Recommended
- Endocrine disruptor
- Builds up in tissue
Women trying to conceive should apply the same precautions as during early pregnancy, since conception timing is often uncertain. The potential endocrine-disrupting properties of 2-methylresorcinol and its structural similarity to compounds with hormonal activity suggest avoiding this ingredient when trying to conceive. Given that safer alternatives exist for brightening and hair coloring, and considering the importance of minimizing exposure to potential endocrine disruptors during the periconception period, discontinuing products with 2-methylresorcinol before trying to conceive is recommended.
2-Methylresorcinol and PCOS
Caution Advised
- Endocrine disruptor
- Interferes with hormones
Women with PCOS have underlying hormonal imbalances, and the potential endocrine-disrupting properties of 2-methylresorcinol raise concerns. While specific studies on this ingredient's effects on PCOS patients don't exist, resorcinol derivatives have shown hormone-modulating effects in research. PCOS involves dysregulation of reproductive hormones, insulin, and androgens. Introducing ingredients with potential endocrine activity could theoretically interfere with hormone balance or PCOS management, though the actual risk from topical cosmetic use is unclear. Given the data gaps and the theoretical risk of hormonal interference, women with PCOS may want to choose alternative ingredients with better-established safety profiles, particularly when addressing skin concerns like hyperpigmentation that commonly occur with PCOS.
2-Methylresorcinol and general use
Caution Advised
- Irritant
- Common allergen
- Endocrine disruptor
2-Methylresorcinol is primarily used in hair dyes and some cosmetic formulations as an antioxidant or colorant. Its structural similarity to resorcinol, which has more established safety concerns, raises questions about its long-term safety profile. The SCCS has noted data gaps regarding resorcinol derivatives and has called for additional safety studies. The ingredient can cause skin irritation, contact dermatitis, and allergic sensitization in some individuals. People with sensitive skin or a history of contact allergies should be particularly cautious. For the general public not in reproductive life stages, the ingredient may be used with awareness of potential irritation and the limited safety data. Patch testing is advisable, and individuals concerned about endocrine-disrupting chemicals may prefer to avoid phenolic compounds with uncertain safety profiles.
Everything else flagged for the same profiles
Related ingredients
Ingredients suggested in place of 2-Methylresorcinol, each one with its own page here.
Ingredients that raise the same concerns.
Where this came from
Truva summarises published guidance from bodies including ACOG, the FDA, the EU SCCS and the Cosmetic Ingredient Review. It has no access to your medical history and it is not a substitute for your doctor, dermatologist or midwife. These assessments have not been reviewed by a clinician, and nothing here is a diagnosis or a prescription. If you are pregnant, breastfeeding or being treated for PCOS, take the ingredient list to the person looking after you.
Assessment last pulled from the ingredient database on .
One ingredient is the easy case.
A label has thirty of them. Truva reads the whole list at once and answers for the profile you set: pregnancy, breastfeeding, postpartum, trying to conceive, PCOS, or general use.
Download on theApp Store